Literature DB >> 12076841

Gabapentin and vigabatrin increase GABA in the human neocortical slice.

Laura D Errante1, Anne Williamson, Dennis D Spencer, Ognen A C Petroff.   

Abstract

The effects of antiepileptic drugs, gabapentin and vigabatrin, on gamma-aminobutyric acid (GABA) concentrations were studied in human (n=14) and rat (n=6) neocortical slice preparations. In this study, neocortical slices were incubated with gabapentin, vigabatrin or no drugs for 3 h in an oxygenated environment. Proton magnetic resonance spectroscopy (MRS) of perchloric acid (PCA) extracts was used to measure GABA concentrations. Vigabatrin increased cellular GABA concentrations in both human and rat neocortical slices by 62% (P<0.001) and 88% (P<0.03), respectively. Gabapentin significantly increased GABA concentrations by 13% (P<0.02) in human neocortical slices made from tissue resected during epilepsy surgery. However, in the rat neocortical slice exposed to the same conditions as the human tissue, gabapentin did not increase GABA significantly. These results confirm our MRS studies in vivo that gabapentin increases GABA levels in epileptic patients, but has minimal or no effect in a healthy rodent model. Caution must be used in extrapolating negative results obtained in rodent models to the human condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076841     DOI: 10.1016/s0920-1211(02)00034-7

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  22 in total

1.  Effect of Primidone on Dentate Nucleus γ-Aminobutyric Acid Concentration in Patients With Essential Tremor.

Authors:  Elan D Louis; Nora Hernandez; Jonathan P Dyke; Ruoyun Ma; Ulrike Dydak
Journal:  Clin Neuropharmacol       Date:  2016 Jan-Feb       Impact factor: 1.592

2.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

Review 3.  Neuroimaging of epilepsy: therapeutic implications.

Authors:  Ruben I Kuzniecky
Journal:  NeuroRx       Date:  2005-04

4.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

Review 5.  GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies.

Authors:  Marisa M Silveri
Journal:  Pharmacol Ther       Date:  2014-03-11       Impact factor: 12.310

6.  Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers.

Authors:  Aryeh I Herman; Andrew J Waters; Sherry A McKee; Mehmet Sofuoglu
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

7.  A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice.

Authors:  T G Tzellos; G Papazisis; K A Toulis; Ch Sardeli; D Kouvelas
Journal:  Hippokratia       Date:  2010-04       Impact factor: 0.471

8.  The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T ¹H-MRS study.

Authors:  Kejia Cai; Ravi Pr Nanga; Lisa Lamprou; Claudia Schinstine; Mark Elliott; Hari Hariharan; Ravinder Reddy; C Neill Epperson
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

Review 9.  Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.

Authors:  Thrasivoulos G Tzellos; Georgios Papazisis; Ekaterini Amaniti; Dimitrios Kouvelas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

Review 10.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.